CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died from...
2025-12-29 7:00 AM EST
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighteen years of navigating...
2025-12-22 7:00 AM EST
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III. CBIH believes that, if the process moves forward, it could represent one of the most consequential...
2025-12-15 7:00 AM EST
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners. As age is a key determinant of reproductive outcomes—and first births are...
2025-10-13 7:00 AM EDT
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder...
2025-10-06 7:00 AM EDT
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas healthcare is experiencing a historic breakthrough with the approval of House Bill 46 (HB 46). Signed into law on June 21, 2025, by Governor Greg Abbott, the expansion of the Texas Compassionate Use Program (TCUP) will cover chronic pain, PTSD, and degenerative neurological conditions, among...
2025-09-29 7:00 AM EDT
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
Houston, Texas--(Newsfile Corp. - November 4, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to announce the appointment of Mr. Charles Tamburello as a new member of the board of directors. His extensive experience in the public markets, which spans nearly three decades, will play a crucial role in driving the company's mergers and acquisitions (M&A) strategy forward. Mr. Tamburello has been instrumental in the success of hundreds of public and private...
2024-11-04 8:00 AM EST
CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings
Houston, Texas--(Newsfile Corp. - October 28, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the ticker symbol CBIH has reached a major milestone in expanding its patent portfolio, filing six utility non-provisional applications for cannabinoid-based therapies that address underserved medical conditions. These patents cover therapeutic innovations for conditions such as pancreatic cancer (No. 18/905,128), breast cancer (No. 18/918,386),...
2024-10-28 8:00 AM EDT
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications. From our desks - Rosangel Andrades and Jennifer Salguero. In the realm of medicine, patent requirements...
2024-07-08 8:00 AM EDT
CBIH Submits Groundbreaking Cannabis Patents for Breast and Pancreatic Cancer Treatments
Houston, Texas--(Newsfile Corp. - July 1, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration. Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic...
2024-07-01 8:00 AM EDT
CBIH's Recently Appointed Director Unveils Groundbreaking Product Strategies and Potential Partnership with Industry Leader
Houston, Texas--(Newsfile Corp. - June 24, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to introduce the groundbreaking strategies formulated by its freshly appointed Treasurer and Director, Mr. John Jones, who has facilitated a series of insightful discussions and established official communications between CBIH and a pioneering company in innovative product and packaging solutions for globally recognized brands. As CBIH prepares for the manufacturing and...
2024-06-24 8:00 AM EDT
CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment
Houston, Texas--(Newsfile Corp. - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California. StoneBridge's assessment highlights CBIH's formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH's...
2024-06-17 8:00 AM EDT
Vita Biotech Retains CBIH Services for Clinical Studies
Houston, Texas--(Newsfile Corp. - June 5, 2024) - Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTC Pink: CBIH), to fund the clinical data collection efforts of CBIH's rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity. Through this strategic alliance, Vita Biotech will act as a financial subsidiary and...
2024-06-05 8:00 AM EDT
Cannabis Bioscience International Holdings Engages StoneBridge Advisory for Comprehensive Company Valuation
Houston, Texas--(Newsfile Corp. - May 29, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) announces the engagement of StoneBridge Advisory (stonebridgema.com) for CBIH's company valuation. The Colorado-based firm specializes in business valuations as well as mergers and acquisitions, boasting over three decades of experience in the industry. They represent businesses for sale, and their expertise lies in in-depth professional valuation reports that are IRS Revenue Ruling...
2024-05-29 8:00 AM EDT
CBIH Engages Prestigious Law Firm for its First Patent Applications
Houston, Texas--(Newsfile Corp. - May 20, 2024) - Cannabis Bioscience International Holdings(OTC Pink: CBIH), utilizing robust methodologies to safeguard its intellectual property and establish a well-defined company portfolio, has engaged Vereb Law Group PLLC (www.vereblawgroup.com), a reputable law firm with headquarters in Houston, which handles all aspects of intellectual property litigation, including matters related to patents, trademarks, copyrights, and trade secrets. CBIH...
2024-05-20 8:00 AM EDT
CBIH Welcomes New Treasurer and Director, Mr. John E. Jones
Houston, Texas--(Newsfile Corp. - May 6, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH), a leading company in the cannabis industry, proudly announces Mr. John E. Jones as its new Treasurer and Director. Mr. Jones is a former 101st Airborne Division sergeant, with an illustrious 35-year career in the business sector, growing an iconic QSR's presence by 80 additional locations as a Franchise Partner, Operator and Chief Executive Officer. Led by his direction, the company...
2024-05-06 8:00 AM EDT
CBIH Commences Clinical Trials of Osteoarthritis Injection "Orthocann"
Houston, Texas--(Newsfile Corp. - March 20, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) has announced the enrollment of the first patient for the clinical trial of its new intra-articular cannabinoid-based injection for knee osteoarthritis. The company plans to test the product on its first participant, and after careful collection and analysis of clinical outcomes, start enrollment of a bigger sample of patients to administer the treatment and further evaluate...
2024-03-20 8:00 AM EDT
CBIH Announces the Retirement of One Billion Shares
Houston, Texas--(Newsfile Corp. - March 6, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) announces that Dante Picazo, its chief executive officer, is contributing one billion shares of his common stock to the Company. These shares will be retired and have the status of authorized and unissued shares. As a result of this contribution, the number of the Company's outstanding shares has been reduced to approximately 9.4 billion. Since current management assumed...
2024-03-06 8:00 AM EST
Brian Cuban Joins Cannabis Bioscience International Holdings as an Advisory Board Member
Houston, Texas--(Newsfile Corp. - February 26, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce that Brian Cuban has been elected by our firm as an Advisory Board Member. Mr. Cuban will bring decades of experience in legal and corporate leadership, and a long track record of coaching diverse professionals around the world. Brian Cuban, the younger brother of the former principal owner of the Dallas Mavericks, Mark Cuban, is an attorney, author, and...
2024-02-26 8:00 AM EST
Cannabis Bioscience International Holdings, Inc. Announces Engagement of Bull in Advantage as its Investor Relations Firm
Houston, Texas--(Newsfile Corp. - February 20, 2024) - Cannabis Bioscience International Holdings, a Houston-based company trading on the OTC Markets under the ticker symbol CBIH, has engaged the services of Bull in Advantage as its Investor Relations firm. About Bull in Advantage, LLC (BIA): Established in 2006, BIA has been providing cutting-edge investor relations, public relations, and digital marketing services to select public companies. We've worked with companies in a wide array of...
2024-02-20 8:00 AM EST